Comparison of characteristics of acquired bilateral nevus of Ota-like macules and nevus of Ota according to therapeutic outcome.
Both acquired bilateral nevus of Ota-like macules (ABNOM) and nevus of Ota are characterized by the presence of dermal melanocytes. There are no differences in the method of treatment, however, postinflammatory hyperpigmentation (PIH) develops more often in ABNOM than in nevus of Ota following treatment. We investigated the differences in the development of PIH after treatment between ABNOM and nevus of Ota, and the histopathologic differences in the PIH. A total of 82 patients with ABNOM (n=47) and nevus of Ota (n=35) were treated with Q-switched alexandrite laser and followed up 2 weeks and 3 months later. Biopsies were performed on lesional skin before treatment. The distribution and the amount of melanin pigments were visualized with Fontana-Masson stain, and the distribution and the depth of melanocytes were measured by GP-100 (NK1-beteb) stain. Clinically, there was more erythema and PIH in ABNOM than in nevus of Ota. Histopathologically, intradermal melanocytes were clustered in groups and dispersed perivascularly in ABNOM, while melanocytes were scattered evenly throughout the dermis in nevus of Ota. Both groups show that when there is a statistically significant number of melanocytes in the perivascular area, erythema and PIH occur after laser therapy. In conclusion, indirect vessel injury in addition to perivascular clustering melanocytes might be considered the cause of increased PIH after treatment in ABNOM.
Lee
Bangjin
B
Department of Dermatology, Ajou University School of Medicine, Suwon, Korea.
Kim
You Chan
YC
Kang
Won Hyoung
WH
Lee
Eun-So
ES
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D006801:Humans; D017495:Hyperpigmentation / Q000473:pathology*; D028022:Low-Level Light Therapy; D008544:Melanocytes / Q000737:chemistry* / Q000166:cytology; D008875:Middle Aged; D009507:Nevus of Ota / Q000473:pathology / Q000628:therapy; D009508:Nevus, Pigmented / Q000473:pathology / Q000628:therapy; D012835:Silver Nitrate; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy; D016896:Treatment Outcome
C051037:Fontana-Masson stain; D012835:Silver Nitrate